Joint Research and Development Agreement on "Human (Allogeneic) Subcutaneous Adipose Tissue-Derived Mesenchymal Stem Cell Sheet (PAL-222) for Patients with Myopic Chorioretinal AtrophyJoint Research and Development Agreement • July 26th, 2023
Contract Type FiledJuly 26th, 2023PharmaBio Corporation (Headquarter: Nagoya, Aichi; President and CEO: Hitoshi Kusano; hereinafter "PharmaBio") and A2 Healthcare Corporation (Headquarter: Bunkyo-ku, Tokyo; President and CEO: Hitoshi Kamiya; hereinafter "A2") have entered into a joint research and development agreement dated July 14, 2023, on "human (allogeneic) subcutaneous adipose tissue-derived mesenchymal stem cell sheet (PAL-222 (*1)) for the treatment of myopic chorioretinal atrophy (hereinafter "this disease")".